AIM ImmunoTech Inc. (AIM)
| Market Cap | 2.06M -81.6% |
| Revenue (ttm) | 88,000 -48.2% |
| Net Income | -13.96M |
| EPS | -8.62 |
| Shares Out | 8.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 717,409 |
| Open | 0.2600 |
| Previous Close | 0.2580 |
| Day's Range | 0.2410 - 0.2621 |
| 52-Week Range | 0.2410 - 19.7180 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+3,852.57%) |
| Earnings Date | May 15, 2026 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also ... [Read more]
Financial Performance
In 2025, AIM ImmunoTech's revenue was $88,000, a decrease of -48.24% compared to the previous year's $170,000. Losses were -$13.96 million, -19.41% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for AIM stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon...
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drug...
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Final UPMC Primary Endpoint Report Details Positive Data fro...
AIM ImmunoTech Transcript: Virtual Investor Closing Bell
Ampligen’s focus on late-stage pancreatic cancer is driven by strong clinical data, significant unmet need, and robust market opportunity. The ongoing phase II DURIPANC study shows positive interim results, with phase III planning underway in partnership with Thermo Fisher Scientific. Orphan drug status and patent protection support long-term value and potential for major partnerships.
AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program
AIM ImmunoTech (AIM) highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, Phase 2 clinical signals, and a strengthening global regulatory...
AIM ImmunoTech Provides Routine Update on Annual Filings
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year e...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: AIM ImmunoTech (AIM), 3,847.63% surge in interest Pipelin...
Why Is AIM ImmunoTech Stock (AIM) Up Today?
AIM ImmunoTech stock gained on Wednesday after it received patent approval for its cancer treatment in Japan.
AIM announces approval of patent for Ampligen in Japan
AIM ImmunoTech (AIM) announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen in combination with checkpoint inhibitors for the tr...
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of panc...
AIM ImmunoTech Announces Closing of its Rights Offering
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and developmen...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: AIM Immunotech (AIM), 32.78% surge in interest Pipeline a...
AIM ImmunoTech announces preliminary results of rights offering
AIM ImmunoTech (AIM) announced the preliminary results of its previously announced rights offering which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights…
AIM ImmunoTech signs agreement for planning of Phase 3 trial of Ampligen
AIM ImmunoTech (AIM) announced an agreement with the PPD clinical research business of Thermo Fisher Scientific (TMO) to design AIM’s anticipated Phase 3 clinical trial in the use of the…
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher...
AIM ImmunoTech reminds stockholders of expiration date for rights offering
AIM ImmunoTech (AIM) announced updated terms for its previously announced rights offering. Each subscription right now entitles holders to purchase one unit, each Unit consisting of one share of the…
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development...
AIM ImmunoTech extends subscription period of rights offering
AIM ImmunoTech (AIM) has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026. The subscription period for the rights…
AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab
AIM ImmunoTech (AIM) announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen combined with AstraZeneca’s (AZN) anti-PD-L1 immune checkpoint ...
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer
OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical st...
AIM ImmunoTech Transcript: Virtual Investor Closing Bell
Ampligen is advancing as a promising therapy for pancreatic cancer, showing strong safety, improved survival, and quality of life in clinical trials. Orphan drug status and robust data support a pivotal Phase 3 trial, with milestones expected soon.
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on Fe...
AIM ImmunoTech Transcript: Corporate Connect Webinar Series
Ampligen is advancing as a novel therapy for late-stage pancreatic cancer, showing significant survival and quality of life benefits in early studies. Ongoing phase II trials with AstraZeneca's Imfinzi are yielding positive interim results, with a phase III trial in planning.
AIM ImmunoTech announces commencement of rights offering
AIM ImmunoTech (AIM) commenced its previously disclosed rights offering. Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company’s common stock, par value…
AIM ImmunoTech Announces Commencement of Rights Offering
OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development...